Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled time : 00:00 save search
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-07 (Crawled : 00:00) - globenewswire.com
REPL | $6.56 -5.88% 310K
|
Health Technology
|
| O: 3.27%
H: 0.13%
C: -4.17%
association presentation cancer cell research meeting skin trial results
LUXH FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages LuxUrban Hotels, Inc. Investors to Secure Counsel Before Important April 12 Deadline in Securities Class Action - LUXH
Published: 2024-04-02 (Crawled : 00:00) - prnewswire.com
LUXH | $0.8912 -2.07% 91K
|
|
| O: -0.71%
H: 2.86%
C: -2.86%
BCDRF | News | $4.978 -8.71% 100
|
Finance
|
| O: 3.9%
H: 4.33%
C: 4.33%
SHLS | $8.275 0.79% 1.4M
|
|
| O: 0.19%
H: 2.0%
C: 0.84%
SAN | News | $4.73 -0.42% 1.9M
|
Finance
|
| O: 1.04%
H: 1.23%
C: 0.82%
deadline trial
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Published: 2024-03-22 (Crawled : 00:00) - globenewswire.com
HCM | $16.44 0.49% 28K
|
Health Technology
|
| O: -4.4%
H: 0.97%
C: -0.73%
eslim-02 antibody anemia trial china
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
Published: 2024-03-19 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
ibi302 macular trial
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
Published: 2024-02-26 (Crawled : 00:00) - biospace.com/
KZR | $0.79 0.31% 240K
|
Health Technology
|
| O: 1.09%
H: 3.74%
C: -1.52%
lupus life approval sciences trial china
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
Published: 2024-02-11 (Crawled : 00:00) - prnewswire.com
ARCT 4 | $25.94 -1.44% 170K
|
Health Technology
|
| O: 0.86%
H: 4.25%
C: 4.1%
csl112 trial results
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2024-02-04 (Crawled : 00:00) - globenewswire.com
PLRX | $12.11 -0.66% 120K
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: -5.78%
liver positive fibrosis bexotegrast trial therapeutics
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa
Published: 2024-01-24 (Crawled : 00:00) - biospace.com/
NTLA | $20.99 -1.55% 560K
|
Health Technology
|
| O: 1.28%
H: 1.0%
C: -4.06%
spvn06 trial
Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients
Published: 2024-01-18 (Crawled : 00:00) - biospace.com/
HOTH | $1.22 3.39% 4.6K
|
Health Technology
|
| O: 5.43%
H: 13.24%
C: 0.74%
ht-001 fda approval treat trial therapeutics
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
Published: 2024-01-09 (Crawled : 00:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.65%
H: 0.69%
C: -0.73%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
INCY | $52.45 -0.7% 530K
|
Health Technology
|
| O: 0.0%
H: 0.53%
C: -2.19%
obesity first chinese key trial
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
Published: 2024-01-04 (Crawled : 00:00) - biospace.com/
GOVX | $1.59 4.61% 8.9K
|
Health Technology
|
| O: 4.19%
H: 0.0%
C: -6.41%
gedeptin cancer trial advanced
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan
Published: 2024-01-04 (Crawled : 00:00) - biospace.com/
CYBN | News | $0.3669 -0.81% 1.2M
|
n/a
|
| O: 0.65%
H: 3.49%
C: 3.49%
first fibromyalgia treatment trial therapeutics
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Published: 2023-12-28 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -1.32%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.08%
H: 0.81%
C: -0.19%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.52%
H: 0.72%
C: -0.34%
INCY | $52.45 -0.7% 530K
|
Health Technology
|
| O: 0.35%
H: 1.07%
C: -0.27%
candidate tumors collaboration trial advanced china therapy
Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia
Published: 2023-12-14 (Crawled : 00:00) - biospace.com/
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
lancet publication schizophrenia trial therapeutics
HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
Published: 2023-12-13 (Crawled : 00:00) - globenewswire.com
HCM | $16.44 0.49% 28K
|
Health Technology
|
| O: -2.54%
H: 3.89%
C: 3.41%
renal cell trial advanced china
BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023
Published: 2023-11-30 (Crawled : 00:00) - biospace.com/
PHGE | News | $0.2897 -2.06% 30K
|
Health Technology
|
| O: 5.4%
H: 3.26%
C: -18.09%
bx004 review positive fibrosis infections trial results
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
Published: 2023-11-30 (Crawled : 00:00) - biospace.com/
ALT | $6.755 -1.96% 2M
|
Commercial Services
|
| O: 1.28%
H: 5.68%
C: -0.32%
obesity momentum positive topline trial results phase 2
Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD
Published: 2023-11-21 (Crawled : 00:00) - globenewswire.com
MESO | $5.16 0.98% 100K
|
Health Technology
|
| O: 6.61%
H: 3.88%
C: 3.88%
blood trials network trial
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
Published: 2023-11-19 (Crawled : 00:00) - globenewswire.com
MNOV | $1.4 9.6K
|
Health Technology
|
| O: 11.8%
H: 8.54%
C: 3.52%
mn-166 meeting trial results glioblastoma
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial
Published: 2023-11-16 (Crawled : 00:00) - biospace.com/
ASND | $138.68 -1.57% 91K
|
Health Technology
|
| O: 0.39%
H: 0.71%
C: 0.18%
trial china phase 2
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.